Creatine for amyotrophic lateral sclerosis/motor neuron disease

scientific article (publication date: 12 December 2012)

Creatine for amyotrophic lateral sclerosis/motor neuron disease is …
instance of (P31):
review articleQ7318358
meta-analysisQ815382
scholarly articleQ13442814

External links are
P356DOI10.1002/14651858.CD005225.PUB3
P698PubMed publication ID23235621

P50authorDaniel M PastulaQ63827259
P2093author name stringDan H Moore
Richard S Bedlack
P2860cites workCreatine for amyotrophic lateral sclerosis/motor neuron diseaseQ24234800
Creatine for amyotrophic lateral sclerosis/motor neuron diseaseQ24244631
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisQ28131805
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosisQ29619074
Amyotrophic lateral sclerosisQ29619516
Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.Q30440341
Comparison of sporadic and familial disease amongst 580 cases of motor neuron diseaseQ33631319
Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseasesQ33917550
The creatine-creatine phosphate energy shuttleQ34194064
ALSFRS-R.Q34362989
The epidemiology of motor neuron diseases: a review of recent studiesQ34417934
Recent advances in amyotrophic lateral sclerosis researchQ35036503
Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.Q35476043
Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatmentQ36488392
Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyQ37613342
Survival of patients with amyotrophic lateral sclerosis in a population-based registryQ38473621
The epidemiology of ALS in Modena, ItalyQ39642568
A simple analysis of the "phosphocreatine shuttle"Q40176885
A clinical trial of creatine in ALS.Q40469445
Regression Models and Life-Tables (with discussion)Q41363019
Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosisQ43744283
Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results.Q43777132
Direct antioxidant properties of creatineQ43846466
A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II.Q43991574
No effect of creatine on respiratory distress in amyotrophic lateral sclerosisQ44025613
A randomized sequential trial of creatine in amyotrophic lateral sclerosisQ44383439
Factors associated with survival in the National Registry of Veterans with ALS.Q44903303
Functional outcome measures as clinical trial endpoints in ALS.Q45158825
Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activityQ46977833
Bipap improves survival and rate of pulmonary function decline in patients with ALS.Q48758870
Prognosis in amyotrophic lateral sclerosis: a population-based study.Q51950008
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).Q53535985
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.Q55032889
Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year periodQ58125373
Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary functionQ72718273
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study GroupQ72759362
The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease RegisterQ72843336
Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998Q74506333
Amyotrophic lateral sclerosis: early predictors of prolonged survivalQ83988720
P921main subjectamyotrophic lateral sclerosisQ206901
P577publication date2012-12-12
P1433published inCochrane Database of Systematic ReviewsQ15750361
P1476titleCreatine for amyotrophic lateral sclerosis/motor neuron disease

Reverse relations

cites work (P2860)
Q34554820ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Q26777929Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis
Q37651130Creatine Revealed Anticonvulsant Properties on Chemically and Electrically Induced Seizures in Mice
Q38691246Creatine for neuroprotection in neurodegenerative disease: end of story?
Q24187191Creatine for women in pregnancy for neuroprotection of the fetus
Q61808045Emergent Prophylactic, Reparative and Restorative Brain Interventions for Infants Born Preterm With Cerebral Palsy
Q90531525Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions
Q92813735Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment
Q36679757Intraspinal stem cell transplantation for amyotrophic lateral sclerosis
Q62785679Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis
Q35630224Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review
Q38772250Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.
Q89645812The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future
Q52673338Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial.
Q38188662Why is ALS so Difficult to Treat?

Search more.